Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid ImagingVillemagne V.L.a, d · Okamura N.e · Pejoska S.d · Drago J.b, c · Mulligan R.S.d · Chételat G.d, f · O’Keefe G.d · Jones G.d · Kung H.F.g · Pontecorvo M.h · Masters C.L.a · Skovronsky D.M.g, h · Rowe C.C.d
aMental Health Research Institute, bHoward Florey Institute, and cCentre for Neuroscience, University of Melbourne, and dDepartment of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Vic., Australia; eDepartment of Pharmacology, Tohoku University School of Medicine, Sendai, Japan; fInserm-EPHE-Université de Caen/Basse-Normandie, Unité U923, GIP Cyceron, CHU Côte de Nacre, Caen, France; gRadiology, University of Pennsylvania, and hAvid Radiopharmaceuticals Inc., Philadelphia, Pa., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Objectives: To evaluate the diagnostic potential of imaging striatal monoaminergic terminal integrity with the novel vesicular monoamine transporter type 2 (VMAT2) radioligand [18F]AV-133 and PET to distinguish DLB from AD. Methods: Fifty participants [9 DLB, 11 AD, 20 Parkinson’s disease (PD) and 10 healthy age-matched control subjects (HC)] underwent [18F]AV-133 PET studies. Additionally, 20 participants underwent amyloid imaging PET scans with either [11C]PiB or 18F-florbetaben. VMAT2 density was calculated through normalized tissue uptake value ratios (RT) at 120–140 min after injection using the primary visual or the cerebellar cortex as reference region. Comparison of the RT for [18F]AV-133 was done between the different clinical diagnostic groups. Results: Significantly lower striatal VMAT2 densities were observed in DLB and PD when compared to AD and HC, especially in the posterior putamen. In contrast to PD and DLB, no reductions were observed in AD patients when compared to HC. Conclusions: [18F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. In contrast to amyloid imaging, VMAT2 imaging with [18F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in DLB patients, assisting in the differential diagnosis from AD.
© 2012 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.